NuvemRx acquires par8o

NuvemRx has acquired par8o from R1 RCM, reinforcing its capabilities in specialty care coordination and 340B referral capture. The $340 billion acquisition enables NuvemRx to broaden its network of services provided to community health centers and expand its footprint in the pharmacy solutions market. This move is intended to integrate more sophisticated referral intelligence, simplify workflows for covered entities, and enhance 340B savings potential.

Through the acquisition of par8o, a company with deep integrations in the healthcare technology space, NuvemRx plans to support over 800 covered entities reaching more than 70 million patients nationwide. Par8o is known for innovation in referral capture services that streamline the process for capturing specialty referrals and ensuring patients are retained within health networks. Integration of par8o’s capabilities with NuvemRx’s services offers substantial improvements in pharmacy care delivery by automating up to 85% of the referral and eligibility processes with AI-powered decision support.

Scott Seidelmann, CEO of NuvemRx, emphasized the critical nature of addressing referral leakage and fragmented specialty care within safety-net organizations. The acquisition is intended to tackle these inefficiencies and support compliance with changing rebate and reimbursement regulations. Par8o's technology is expected to enhance NuvemRx’s ability to provide real-time referral visibility, thus reducing administrative burdens and optimizing patient care.

This development comes against the backdrop of increasing complexity in the 340B program and growing demands for more integrated health care delivery solutions. NuvemRx aims to respond to these dynamics by offering an all-encompassing solution that aligns third-party administration, pharmacy management, and referral capture services within one entity. Melissa Opraseuth, COO of par8o, will join NuvemRx's leadership, symbolizing a seamless integration of expertise and mission.

As the acquisition progresses, future milestones will focus on operational integration and customer transition under the newly combined entity. While there is no indication of significant regulatory hurdles, the focus remains on delivering streamlined services to safety-net providers and amplifying patient access across the country. The transformed NuvemRx is poised to play an influential role in the healthcare technology sector, setting new benchmarks for managing the intricate 340B landscape.